Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Developing a Diagnostic Tool, Using SPAG5, for Predicting Clinical Benefit From Standard Anthracycline Combination (AC) in Breast Cancer

NCT04277195 is registered in ClinicalTrials.gov with Nottingham University Hospitals NHS Trust as lead sponsor.

NCT NCT04277195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04277195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Developing a Diagnostic Tool, Using SPAG5, for Predicting Clinical Benefit From Standard Anthracycline Combination (AC) in Breast Cancer
Lead sponsor
Nottingham University Hospitals NHS Trust
Phase
Observational
Overall status
Unknown status
Start date
November 7, 2019
Completion date
May 31, 2021
Enrollment
4,750 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer